Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 9/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904859 | 0.94 | DRD2 (0.58) | DRD2SLC6A4KCNA3CCR3CCR1 | |
| SCHEMBL30659491 | 0.76 | KCNA3 (0.75) | DRD2KCNA3RAB9ANPSR1CCR3 | |
| SCHEMBL5858616 | 0.75 | DRD2 (0.69) | DRD2SLC6A4KCNA3AKT1OPRM1 | |
| SCHEMBL904833 | 0.74 | CCR3 (0.57) | KCNA3CCR3CCR1 | |
| SCHEMBL3132276 | 0.74 | DRD2 (0.67) | DRD2SLC6A4AKT1OPRM1KMT2A | |
| SCHEMBL11712812 | 0.74 | KCNA3 (1.00) | DRD2KCNA3RAB9ANPSR1CCR3 | |
| Hydrochloric Acid SCHEMBL11625263 | 0.74 | KCNA3 (0.97) | DRD2KCNA3RAB9ANPSR1CCR3 | |
| SCHEMBL5858744 | 0.72 | DRD2 (0.68) | DRD2SLC6A4OPRM1KMT2AOPRL1 | |
| SCHEMBL3754922 | 0.72 | DRD2 (0.65) | DRD2SLC6A4NPSR1AKT1OPRM1 | |
| SCHEMBL11599560 | 0.72 | KCNA3 (0.66) | DRD2KCNA3RAB9ANPSR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989393-B2 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1265870-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | AstraZeneca AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001066525-A1 | NEW CCR5 MODULATORS: BENZIMIDAZOLES OR BENZOTRIAZOLES | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119869-A1 | Ccr5 modulators benzimidazoles or benzotriazoles | CCR5, CCR2, CXCR4 | DRD2 1216/4885SLC6A4 696/4885KCNA3 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.